http://www.masshightech.com/displayarticledetail.asp?Art_ID=60588
Avant to test anthrax vaccine at Walter Reed |
| 10/15/2002 10:17 AM |
| By Patricia Resende |
| Avant Immunotherapeutics Inc. and its
partner, DynPort Vaccine Co. LLC (DVC) of Reston, Va., have entered into a
Phase I clinical trial of an injectable anthrax vaccine. The Needham-based company and DynPort will administer the vaccine, which consists of a protective antigen derived from anthrax bacterium, to nearly 70 volunteers. DVC is a joint venture between DynCorp. and Porton International Inc. in Washington, D.C. The trial will be held at the Walter Reed Army Institute of Research in Maryland in collaboration with the Henry M. Jackson Foundation and will study the safety of DynPort’s vaccine being developed for the Department of Defense. In pre-clinical animal trials, the vaccine was found to be “safe and well-tolerated.” “We are very pleased to have reached the important milestone of taking this injectable anthrax vaccine candidate into the clinic,” said Una S. Ryan, president and chief executive at Avant, in a release. |
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.